Skip to main content

Leiden, The Netherlands, October 28, 2021 – Batavia Biosciences is pleased to announce today that they are the manufacturing partner of IAVI’s Sudan ebolavirus vaccine candidate, rVSV∆G-SUDV-GP. The clinical trial material will be manufactured using Batavia’s highly intensified vaccine manufacturing platform, HIP-Vax®, allowing low cost of goods and  a substantial reduction in time moving from bench to clinic.

Yesterday, IAVI announced that it has been awarded a US$126 million grant from the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services to further develop their VSV-vector based Sudan ebolavirus vaccine candidate (rVSV∆G-SUDV-GP). Batavia, as IAVI’s manufacturing partner will aid IAVI with the production of the vaccine. Currently, there is no licensed vaccine available against the Sudan ebolavirus. This highly virulent virus causes intermittent outbreaks of hemorrhagic fever in Africa. For the Zaire ebolavirus, there is a licensed vaccine available based on a VSV-vector, named Ervebo. rVSV∆G-SUDV-GP is built on the same backbone.

“The rising number of viral hemorrhagic fever outbreaks underscores the need to prioritize pandemic preparedness vaccine development and testing. As we’ve seen with COVID-19, a local outbreak one day can become a lethal pandemic the next in the absence of a widely available and accessible vaccine,” said Swati Gupta, Dr.P.H., M.P.H., vice president and head of emerging infectious diseases and epidemiology, IAVI.

Menzo Havenga, Ph.D., Chief Executive Officer, Batavia Biosciences, comments: “We look forward to aiding IAVI and to helping accelerate the development of this important vaccine. Batavia Biosciences strives to significantly reduce human suffering from infectious diseases and cancer, and thus this vaccine is of critical importance given the high mortality rate associated with ebolavirus infection.”

HIP-Vax highly intensified manufacturing

Batavia Biosciences, being IAVI’s manufacturing partner for all their rVSV-vector based vaccine candidates, has developed a platform process for IAVIs rVSV-vector using HIP-Vax. HIP-Vax uses state-of-the-art bioprocess intensification techniques to have a highly concentrated production harvest. This results in a significantly lower cost of goods compared to traditional manufacturing platforms. Additionally, because we already have everything in place for this specific vector, we expect to deliver the clinical trials material within nine months after project initiation.

“This innovative platform is a gamechanger for vaccine development and epidemic preparedness, improving vaccines’ availability and affordability,” concludes Chris Yallop, Ph.D., Chief Operations Officer, Batavia Biosciences.